Key Drivers
- Gross Margin
- Cash Burn
- Leverage Pressure
AIAI Summary
Ionis has finally gained a real commercial anchor with TRYNGOLZA and added validation through the Recordati deal, but the investment case now depends on proving fast enough uptake and cash generation to offset persistent burn and justify an already rich valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •Leverage Pressure
IONS has exceptional gross margins and solid short-term liquidity, but persistent operating losses, heavy R&D burn, declining cash, and meaningful leverage make it a high-risk, richly valued stock.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Support holding
- •Stretched move
Over the last month, IONS broke out from the low $73s to $81.80 with higher highs and higher lows, keeping $79-$80 as near-term support and $81-$82 as resistance, though the move looks stretched and may pause or pull back.
Broke out sharply from the low $73s to $81.80 in the last month, signaling strong momentum and short-term extension
Sentiment & News
Key News Insights:
- •TRYNGOLZA launch
- •Global licensing
- •Board expansion
Ionis is shifting decisively toward commercialization, led by FDA approval and label expansion of TRYNGOLZA, a U.S.-focused partnership for zilganersen outside the U.S., and fresh board leadership as it advances its RNA pipeline.
This is a positive catalyst for Ionis, strengthening its near-term revenue outlook while underscoring its transition into a commercial-stage biotech
Similar Companies in Healthcare
Other companies in the same sector with AI ratings